Inventiva S.A. — Investor Relations & Filings

Inventiva S.A. is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies that target nuclear receptors and transcription factors. The company's primary focus is on diseases with significant unmet medical needs, including fibrosis and metabolic disorders. Its lead product candidate, lanifibranor, is a pan-PPAR agonist in development for the treatment of non-alcoholic steatohepatitis (NASH). Lanifibranor is designed to address the key features of NASH, including inflammation, steatosis, ballooning, and fibrosis. Following positive Phase IIb results, the U.S. Food and Drug Administration (FDA) granted lanifibranor Breakthrough Therapy Designation. The candidate is currently being evaluated in a pivotal Phase III clinical trial (NATiV3).